title: 2-Chloroadenosine decreases tyrosylprotein sulfotransferase activity in the Golgi apparatus in PC12 cells. Evidence for a novel receptor.
abstract: In the present studies, we investigated the activity of tyrosylprotein sulfotransferase (TPST) in the Golgi apparatus of PC12 cells and the regulation of this enzyme by 2-chloroadenosine, an adenosine receptor agonist. Studies employing continuous sucrose gradient and trypsinization of the membranes demonstrate that TPST is located on the luminal side of Golgi apparatus in PC12 cells. Treatment of PC12 cells with 2-chloroadenosine results in a dose-dependent decrease of TPST activity which is observable as early as 3 h after initiation of treatment, maximizes at 24-48 h with continuous exposure, and is readily reversible upon removal of the drug. While forskolin, an agent that directly increases intracellular cAMP, has no effect on TPST activity, 2-chloroadenosine equally suppressed the enzyme activity in both the wild type and a protein kinase A-deficient mutant strain of PC12 cells, indicating that such regulation of TPST activity by 2-chloroadenosine was independent of cAMP-dependent protein phosphorylation. This effect of 2-chloroadenosine can be potentiated by an adenosine uptake blocker dipyridamole but cannot be elicited by other adenosine A1 or A2 receptor agonists, further suggesting that TPST activity in PC12 cells is regulated by 2-chloroadenosine via a novel membrane receptor. Incubation of the cells with cyclo heximide, a protein synthesis inhibitor, also led to a time- and dose-dependent suppression of TPST activity. At concentrations of cycloheximide that produced maximal inhibition (approximately 50%), cotreatment with 2-chloroadenosine did not lead to a further decrease of the TPST activity. These results suggest that the sensitivity of TPST activity to be controlled by protein synthesis provides a mechanism for regulation of its activity by 2-chloroadenosine.
authors.affiliation: Department of Pharmacology and Therapeutics, School of Medicine and Biomedical Sciences, State University of New York, Buffalo 14214.
authors.forename: W H
authors.initials: WH
authors.lastname: Lin
authors.forename: K A
authors.initials: KA
authors.lastname: Marcucci
authors.forename: R A
authors.initials: RA
authors.lastname: Rabin
authors.forename: J A
authors.initials: JA
authors.lastname: Roth
mesh_terms: D015762:2-Chloroadenosine / Q000494:pharmacology*; D002460:Cell Line; D005576:Colforsin / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D003513:Cycloheximide / Q000494:pharmacology; D005700:Galactosyltransferases / Q000378:metabolism; D006056:Golgi Apparatus / Q000737:chemistry / Q000201:enzymology*; D010766:Phosphorylation; D011983:Receptors, Purinergic / Q000032:analysis / Q000187:drug effects* / Q000378:metabolism; D015238:Sulfotransferases / Q000378:metabolism*; D014357:Trypsin / Q000737:chemistry
chemical_list: D011983:Receptors, Purinergic; D015762:2-Chloroadenosine; D005576:Colforsin; D003513:Cycloheximide; D000242:Cyclic AMP; D005700:Galactosyltransferases; D015238:Sulfotransferases; C039079:protein-tyrosine sulfotransferase; D014357:Trypsin